Coronary atherosclerotic heart disease
Conditions
Interventions
Conventional treatment group:Conventional treatment
Integrated traditional Chinese and Western medicine treatment group:huoxuexiaozheng powder
Sponsors
First Affiliated Hospital of Zhejiang Chinese Medicine University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 35-85 years in the Department of Cardiology in our hospital; 2. Patients with good compliance who have not taken other Chinese medicines; 3. Patients who regularly take statins and anti-platelet aggregation drugs; 4. After informed consent to receive medical history collection, follow-up and need to collect fasting 12h venous blood samples 2 times.
Exclusion criteria
Exclusion criteria: (1) Patients with infection, fever, trauma, burns, surgical history, or active tuberculosis or rheumatic immune disease in the last week; (2) Severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc.) with hemodynamic changes; (3) Patients with chronic heart failure stage C (stage C refers to the stage of clinical heart failure, the patient has a basic structural heart disease, past or current symptoms such as shortness of breath, fatigue, decreased exercise tolerance or other signs of heart failure); (4) valvular heart disease (moderate or above a valve) or primary cardiomyopathy; (5) Patients with acute exacerbation of chronic obstructive pulmonary disease or pulmonary heart disease or respiratory failure; (6) patients with acute and subacute cerebrovascular disease; (7) known severe renal insufficiency, serum creatinine (Cr) male> 221umol / L, female> 177umol / L; (8) known severe hepatic insufficiency, alanine aminotransferase (ALT)> 3 times normal, or with cirrhosis; (9) Combining severe primary diseases such as hematopoietic system or malignant tumors; (10) organ transplant patients; (11) Pregnant and lactating women; (12) autoimmune diseases, hypothyroidism or SLE patients; (13) Those who took immunomodulators and steroid hormones within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VCAM-1;miRNA-126;TC;TG;LDL-C;HDL-C;Hs-CRP;Hcy;Seattle Angina Scale Score;TCM symptom score;Total plaque score;SSS; | — |
Countries
China
Contacts
Public ContactLiu Qiang
First Affiliated Hospital of Zhejiang Chinese Medicine University
Outcome results
None listed